VORSCHAU
Frühere Meldungen
PRESSETERMINE
AKTUELLES PRESSEFOTO
IR Nachrichten
21.05.2024 10:25
Addiko Bank AG
21.05.2024 10:20
Addiko Bank AG
21.05.2024 10:06
Frequentis AG
EUROPA NACHRICHTEN
ADHOC
Mi, 17.04.2024 12:00
pta20240417019
Business news for the stock market
Medigene AG: Medigene to Present at Upcoming Scientific ConferencesPlanegg/Martinsried (pta019/17.04.2024/12:00) - Medigene AG ( http://www.medigene.com ) (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 - May 1, 2024. The presentations will be available on Medigene´s website after the conferences: https://medigene.com/science/abstracts/ Oral presentation:
CHI's 8th Annual Immuno-Oncology Summit Europe 2024
The work to be presented will highlight the Company's lead candidate MDG1015, a first-in-class, third generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1/ LAGE-1a (New York oesophageal squamous cell carcinoma 1 / L Antigen Family Member-1a), armored and enhanced with the PD1-41BB costimulatory switch protein (CSP). A first-in-human trial for MDG1015 is planned for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024. Oral presentation:
7th International Neoantigen Summit 2024
Dr. Longinotti will summarize the generation process of optimal affinity 3S (sensitive, specific and safe) TCRs targeting various Kirsten rat sarcoma virus specific mutations (mKRAS), armored and enhanced with the PD1-41BB CSP. In vitro data will showcase how armoring tools such as the PD1-41BB CSP can enhance TCR-T cell functionality, and will also illustrate how the composition of the drug product can be optimized for safety, efficacy and durability. --- end of press release ---
About Medigene AG
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene AG
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
(Ende)
FOTODIENST
PRESSETEXT.TV
Walter Oblin sieht Post auf Wachstumskurs 18.04.2023 ETARGET
FOCUSTHEMA
SPECIALS
Werbung
middleAdvertising
|